Your browser doesn't support javascript.
loading
Quality of life in patients with hereditary angioedema in Canada.
Lee, Erika Yue; Hsieh, Jane; Borici-Mazi, Rozita; Caballero, Teresa; Kanani, Amin; Lacuesta, Gina; McCusker, Christine; Waserman, Susan; Betschel, Stephen.
Afiliação
  • Lee EY; Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Division of Clinical Immunology and Allergy, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. Electronic address: erika.lee@mail.utoronto.ca.
  • Hsieh J; Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Borici-Mazi R; Division of Allergy and Immunology, Department of Medicine, Queen's University, Kingston, Ontario, Canada.
  • Caballero T; Allergy Department, Hospital Universitario La Paz, Hospital La Paz Institute for Health Research (IdiPaz), Biomedical Research Network on Rare Diseases (CIBERER U754), Madrid, Spain.
  • Kanani A; Division of Allergy and Immunology, Department of Medicine, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.
  • Lacuesta G; Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
  • McCusker C; Division of Pediatric Allergy and Immunology, McGill University Health Centre Research Institute, Montreal, Québec, Canada.
  • Waserman S; Division of Clinical Immunology and Allergy, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
  • Betschel S; Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Division of Clinical Immunology and Allergy, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
Ann Allergy Asthma Immunol ; 126(4): 394-400.e3, 2021 04.
Article em En | MEDLINE | ID: mdl-33450396
ABSTRACT

BACKGROUND:

Hereditary angioedema (HAE) is associated with decreased quality of life (QoL), which has typically been measured using a generic non-disease-specific questionnaire.

OBJECTIVE:

We aimed to assess the QoL in patients with HAE type I and II in Canada using a previously validated HAE-specific questionnaire.

METHODS:

An online questionnaire was sent to the members of two Canadian HAE patient groups to collect data on demographics, HAE clinical course, and QoL scores. All patients 18 years of age or older with HAE type I or II were eligible. The impact of the available clinical factors on the QoL scores was evaluated. Multiple linear regression was performed using clinically relevant factors to predict HAE QoL outcome.

RESULTS:

Among the 72 patients in the study, the mean total HAE QoL score was 102 (±23) (SD) on a scale of 25 to 135, with higher scores indicating better QoL. Although the total QoL scores correlated positively with patients' level of satisfaction and perceived control (P < .001 for both), it correlated negatively with the number of acute attacks (P = .03). Yet, the types of treatment did not have an impact on the QoL. Predictors, including sex, comorbidities, and the number of attacks, only explained 12% of the variance in the total QoL scores.

CONCLUSION:

HAE continues to impair QoL in Canadian patients despite receiving recommended treatment. Although the frequency of attacks affects QoL, patients' experience with their HAE care also affects QoL substantially. The study highlights the importance of considering patients' experience with their HAE care as physicians develop an appropriate management plan.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Angioedemas Hereditários Tipo de estudo: Prognostic_studies Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Angioedemas Hereditários Tipo de estudo: Prognostic_studies Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Ano de publicação: 2021 Tipo de documento: Article